Stay updated with breaking news from Pharmaxis Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PXS-5505 shows good tolerability and >90% inhibition of target enzymes LOX and LOXL2 in myelofibrosis phase 1c dose escalation study Safety committee approves progression to 6 month phase 2 study SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial...
PXS-5505 shows good tolerability and >90% inhibition of target enzymes LOX and LOXL2 in myelofibrosis phase 1c dose escalation study...
A research team at the University of Rochester Medical Center in New York State has been investigating the role of lysyl oxidase enzymes in liver...
/PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced results of data analysis from the second of three stages in...
13:48 Thu 01 Jul 2021 S&P/ASX 200 dips on the first day of FY22 after closing out its best year on record OPEC+ may discuss on Thursday about extending the current oil production cuts beyond its original end date of April 2022. The crude oil price is near multi-year highs and recorded its seventh monthly gain in the past eight months. S&P/ASX 200 (INDEXASX:XJO) has slipped 0.48% to 7,277.6 following mixed moves overnight on Wall Street, with the S&P 500 hitting another record high while the Nasdaq fell 0.2%. The local index has surged 24% in the last 12 months for its best year on...